[go: up one dir, main page]

MA40609B1 - Agents de liaison cd123 et leurs utilisations - Google Patents

Agents de liaison cd123 et leurs utilisations

Info

Publication number
MA40609B1
MA40609B1 MA40609A MA40609A MA40609B1 MA 40609 B1 MA40609 B1 MA 40609B1 MA 40609 A MA40609 A MA 40609A MA 40609 A MA40609 A MA 40609A MA 40609 B1 MA40609 B1 MA 40609B1
Authority
MA
Morocco
Prior art keywords
binding fragments
antibodies
binding agents
relates
antigen binding
Prior art date
Application number
MA40609A
Other languages
English (en)
Inventor
John Wheeler
Alexey Teplyakov
Francois Gaudet
Ricardo Attar
Benjamin C Harman
Yingzhe Li
Jinquan Luo
Ronan Mcdaid
Steven C Pomerantz
Susan H Tam
Sheng-Jiun Wu
Jennifer F Nemeth
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40609B1 publication Critical patent/MA40609B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des anticorps qui se lient de manière immunospécifique à cd123. L'invention concerne également des polynucléotides associés susceptibles de coder pour les anticorps fournis spécifiques au cd123 ou des fragments de liaison à l'antigène, des cellules exprimant les anticorps fournis ou les fragments de liaison, ainsi que des vecteurs associés et des anticorps marqués de manière détectable ou des fragments de liaison à l'antigène marqués de manière détectable. En outre, l'invent
MA40609A 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations MA40609B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05
PCT/US2015/048316 WO2016036937A1 (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA40609B1 true MA40609B1 (fr) 2020-05-29

Family

ID=54150667

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40609A MA40609B1 (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations
MA053145A MA53145A (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053145A MA53145A (fr) 2014-09-05 2015-09-03 Agents de liaison cd123 et leurs utilisations

Country Status (39)

Country Link
US (1) US9850310B2 (fr)
EP (2) EP3722315A1 (fr)
JP (2) JP6805130B2 (fr)
KR (1) KR102540192B1 (fr)
CN (1) CN107074956B (fr)
AR (1) AR101765A1 (fr)
AU (1) AU2015311931B2 (fr)
CA (1) CA2959171C (fr)
CL (1) CL2017000515A1 (fr)
CO (1) CO2017002196A2 (fr)
CR (1) CR20170079A (fr)
CY (1) CY1122858T1 (fr)
DK (1) DK3189081T3 (fr)
EA (1) EA037647B1 (fr)
EC (1) ECSP17020812A (fr)
ES (1) ES2791249T3 (fr)
HR (1) HRP20200745T1 (fr)
HU (1) HUE048791T2 (fr)
IL (1) IL250770B (fr)
JO (1) JO3568B1 (fr)
LT (1) LT3189081T (fr)
MA (2) MA40609B1 (fr)
ME (1) ME03724B (fr)
MX (1) MX384424B (fr)
MY (1) MY186337A (fr)
NI (1) NI201700025A (fr)
PE (1) PE20171556A1 (fr)
PH (1) PH12017500472A1 (fr)
PL (1) PL3189081T3 (fr)
PT (1) PT3189081T (fr)
RS (1) RS60305B1 (fr)
SG (1) SG11201701599UA (fr)
SI (1) SI3189081T1 (fr)
SM (1) SMT202000253T1 (fr)
TW (1) TWI693233B (fr)
UA (1) UA120060C2 (fr)
UY (1) UY36289A (fr)
WO (1) WO2016036937A1 (fr)
ZA (1) ZA201702369B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066339A (zh) * 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
KR102680151B1 (ko) 2015-01-23 2024-07-03 사노피 항-ｃｄ3 항체, 항-ｃｄ123 항체, 및 ｃｄ3 및/또는 ｃｄ123에 특이적으로 결합하는 이중특이적 항체
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
PT3313884T (pt) * 2015-06-29 2021-02-25 Immunogen Inc Anticorpos anti-cd123 e conjugados e derivados dos mesmos
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN116987189A (zh) * 2016-05-20 2023-11-03 哈普恩治疗公司 单链可变片段cd3结合蛋白质
CA3025995C (fr) 2016-06-06 2023-08-08 F. Hoffmann-La Roche Ag Proteines hybrides utilisees en ophtalmologie et assurant une meilleure retention oculaire
KR20190015520A (ko) 2016-06-07 2019-02-13 마크로제닉스, 인크. 조합 치료법
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
MX2019003225A (es) * 2016-09-21 2019-06-10 Aptevo Res & Development Llc Proteínas de unión a cd123 y composiciones y métodos relacionados.
AU2017363302A1 (en) 2016-11-23 2019-06-27 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
MX2019006043A (es) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Proteína de unión de antígeno prostático específico de membrana.
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
CA3049689A1 (fr) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions et methodes pour augmenter la signalisation de recepteurs mediee par des anticorps
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
EP3589662A4 (fr) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
WO2018166461A1 (fr) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
BR112019023856A2 (pt) 2017-05-12 2020-06-09 Harpoon Therapeutics Inc proteínas triespecíficas que visam msln e métodos de utilização
WO2019034580A1 (fr) 2017-08-14 2019-02-21 Morphosys Ag Anticorps humanisés pour cd3
US20210061911A1 (en) * 2017-09-07 2021-03-04 Macrogenics, Inc. Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018357221B2 (en) * 2017-10-27 2025-08-28 Pfizer Inc. Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
AU2018385409A1 (en) 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
JP2021523192A (ja) 2018-05-14 2021-09-02 ハープーン セラピューティクス，インク． 免疫グロブリン分子の条件的活性化のための結合部分
KR20220080044A (ko) * 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
JOP20200295A1 (ar) 2018-05-24 2020-11-22 Janssen Biotech Inc أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CA3114038A1 (fr) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Proteines de liaison a dll3 et methodes d'utilisation
EP3882266A4 (fr) * 2018-10-17 2022-07-27 Good T Cells, Inc. Molécule de liaison spécifique à la protéine lrig-1, et utilisation associée
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
JP7566766B2 (ja) * 2019-03-11 2024-10-15 ヤンセン バイオテツク，インコーポレーテツド 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
BR112021022089A2 (pt) * 2019-05-08 2022-02-08 Janssen Biotech Inc Materiais e métodos para modulação da imunidade mediada por células t
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
CN113912697B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白与应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
MX2022010228A (es) 2020-02-21 2022-09-19 Macrogenics Inc Moleculas de union a cd137 y usos de las mismas.
CA3171113A1 (fr) 2020-03-13 2021-09-16 Patrick John DOONAN Materiaux et procedes de liaison de siglec-3/cd33
WO2021236841A2 (fr) 2020-05-19 2021-11-25 The Regents Of The University Of California Polypeptides et vaccins conjugués d'induction de réponses immunitaires
WO2021234560A1 (fr) 2020-05-19 2021-11-25 Janssen Biotech, Inc. Compositions comprenant un agent thérapeutique de redirection des lymphocytes t et un inhibiteur de la voie d'adhésion vla 4
WO2022056192A1 (fr) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Méthodes et compositions pour moduler l'immunité médiée par la chaîne bêta
WO2022087458A1 (fr) * 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions avec des molécules de liaison à l'antigène cd8 pour moduler la fonction de cellules immunitaires
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
MX2023013791A (es) 2021-05-18 2024-02-13 Janssen Biotech Inc Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44.
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
AU2022326544A1 (en) * 2021-08-09 2024-02-29 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023138666A1 (fr) * 2022-01-19 2023-07-27 Utc Therapeutics (Shanghai) Co., Ltd. Arn circulaire et son utilisation
CA3247475A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
WO2023227790A1 (fr) 2022-05-27 2023-11-30 Sanofi Agents d'activation de cellules tueuses naturelles (nk) se liant aux variants nkp46 et bcma avec ingénierie de fc
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
EP1538206B1 (fr) 1997-09-16 2010-03-24 Centocor, Inc. Synthèse chimique complète et synthèse de gènes et de génomes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
EP2949673A1 (fr) * 2009-04-27 2015-12-02 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-il-3ra destiné à être utilisé dans le traitement d'une tumeur sanguine
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
CN102597775A (zh) * 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
EP4053162A1 (fr) * 2012-05-18 2022-09-07 Aptevo Research and Development LLC Immunofusion bispécifique (ifb) de scfv se liant au cd123 et cd3

Also Published As

Publication number Publication date
WO2016036937A1 (fr) 2016-03-10
UY36289A (es) 2016-04-01
CO2017002196A2 (es) 2017-07-28
MA53145A (fr) 2021-05-19
SG11201701599UA (en) 2017-03-30
JP6805130B2 (ja) 2020-12-23
CA2959171C (fr) 2023-11-14
JO3568B1 (ar) 2020-07-05
JP2021050216A (ja) 2021-04-01
CR20170079A (es) 2017-04-27
TWI693233B (zh) 2020-05-11
MX384424B (es) 2025-03-14
CY1122858T1 (el) 2021-05-05
TW201625687A (zh) 2016-07-16
ZA201702369B (en) 2018-12-19
EA037647B1 (ru) 2021-04-27
KR20170049554A (ko) 2017-05-10
US20160068605A1 (en) 2016-03-10
EA201790530A1 (ru) 2018-03-30
US9850310B2 (en) 2017-12-26
DK3189081T3 (da) 2020-05-04
ECSP17020812A (es) 2018-07-31
PT3189081T (pt) 2020-05-25
CN107074956A (zh) 2017-08-18
IL250770A0 (en) 2017-04-30
HRP20200745T1 (hr) 2020-08-07
ES2791249T3 (es) 2020-11-03
JP2017529838A (ja) 2017-10-12
AU2015311931B2 (en) 2020-09-03
ME03724B (fr) 2021-01-20
CN107074956B (zh) 2021-11-26
EP3189081B1 (fr) 2020-02-19
RS60305B1 (sr) 2020-07-31
PL3189081T3 (pl) 2020-10-05
SMT202000253T1 (it) 2020-07-08
BR112017004322A2 (pt) 2017-12-05
HUE048791T2 (hu) 2020-09-28
MX2017002891A (es) 2017-10-11
AR101765A1 (es) 2017-01-11
LT3189081T (lt) 2020-05-11
UA120060C2 (uk) 2019-09-25
PH12017500472A1 (en) 2017-07-31
MY186337A (en) 2021-07-13
AU2015311931A1 (en) 2017-03-16
PE20171556A1 (es) 2017-10-27
IL250770B (en) 2020-10-29
EP3189081A1 (fr) 2017-07-12
NI201700025A (es) 2017-06-22
CA2959171A1 (fr) 2016-03-10
CL2017000515A1 (es) 2018-03-16
SI3189081T1 (sl) 2020-07-31
KR102540192B1 (ko) 2023-06-02
EP3722315A1 (fr) 2020-10-14

Similar Documents

Publication Publication Date Title
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
SA520420631B1 (ar) الأجسام المضادة لـ cd3 واستخداماتها
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA38498B1 (fr) Protéines de liaison anti-lag-3
PH12014502184A1 (en) Anti-hla-b* 27 antibodies and uses thereof
JO3798B1 (ar) الأجسام المضادة ملزمة على وجه التحديد pd-1 واستخداماتها
MX383216B (es) Anticuerpos dirigidos contra la inmunoglobulina de células t y la proteína mucina 3 (tim-3).
NZ718280A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MY161435A (en) Anti-vegf antibodies and polynucleotides encoding the same
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
SG196839A1 (en) Antibodies against fcrn and use thereof
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MA39090A1 (fr) Anticorps anti-ccl17
CL2020002459A1 (es) Variantes de anticuerpo c-terminales